Replimune Group, Inc. (NASDAQ:REPL) Receives $21.00 Consensus Target Price from Analysts

Replimune Group, Inc. (NASDAQ:REPL) has received a consensus recommendation of “Moderate Buy” from the ten ratings firms that are presently covering the stock, Marketbeat Ratings reports. Four analysts have rated the stock with a hold recommendation, five have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $11.38.

Several equities analysts have issued reports on the company. Jefferies Financial Group dropped their price objective on Replimune Group from $31.00 to $6.00 and set a “buy” rating on the stock in a report on Tuesday. JPMorgan Chase & Co. reaffirmed a “neutral” rating and set a $9.00 price objective (down previously from $19.00) on shares of Replimune Group in a report on Tuesday. Cantor Fitzgerald assumed coverage on Replimune Group in a report on Friday, June 20th. They set an “overweight” rating on the stock. Leerink Partners reaffirmed a “market perform” rating and set a $3.00 price objective on shares of Replimune Group in a report on Tuesday. Finally, HC Wainwright reissued a “buy” rating and set a $22.00 price target on shares of Replimune Group in a report on Thursday, July 3rd.

Replimune Group Stock Down 77.2%

REPL stock opened at $2.81 on Friday. The firm has a market cap of $216.62 million, a PE ratio of -0.92 and a beta of 0.61. The company has a debt-to-equity ratio of 0.17, a quick ratio of 7.95 and a current ratio of 7.95. The firm’s 50 day moving average price is $9.62 and its 200-day moving average price is $10.46. Replimune Group has a one year low of $2.68 and a one year high of $17.00.

Replimune Group (NASDAQ:REPL) last announced its earnings results on Thursday, May 22nd. The company reported ($0.82) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.07). During the same quarter in the prior year, the firm earned ($0.25) earnings per share. On average, equities research analysts anticipate that Replimune Group will post -2.97 EPS for the current year.

Insider Buying and Selling at Replimune Group

In other Replimune Group news, CEO Sushil Patel sold 25,105 shares of the business’s stock in a transaction on Tuesday, May 20th. The shares were sold at an average price of $8.06, for a total value of $202,346.30. Following the transaction, the chief executive officer owned 343,576 shares in the company, valued at $2,769,222.56. The trade was a 6.81% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Christopher Sarchi sold 3,749 shares of the business’s stock in a transaction on Tuesday, May 20th. The stock was sold at an average price of $8.05, for a total transaction of $30,179.45. Following the completion of the transaction, the insider owned 128,296 shares in the company, valued at $1,032,782.80. This represents a 2.84% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 74,907 shares of company stock worth $603,655. Corporate insiders own 8.80% of the company’s stock.

Institutional Investors Weigh In On Replimune Group

A number of institutional investors have recently modified their holdings of the stock. Sterling Capital Management LLC grew its position in Replimune Group by 364.5% in the 4th quarter. Sterling Capital Management LLC now owns 2,109 shares of the company’s stock worth $26,000 after purchasing an additional 1,655 shares during the last quarter. US Bancorp DE boosted its stake in Replimune Group by 582.6% in the 1st quarter. US Bancorp DE now owns 4,594 shares of the company’s stock worth $45,000 after purchasing an additional 3,921 shares during the period. Tower Research Capital LLC TRC boosted its stake in Replimune Group by 696.7% in the 4th quarter. Tower Research Capital LLC TRC now owns 6,772 shares of the company’s stock worth $82,000 after purchasing an additional 5,922 shares during the period. Aster Capital Management DIFC Ltd boosted its stake in shares of Replimune Group by 8,798.9% during the 4th quarter. Aster Capital Management DIFC Ltd now owns 8,276 shares of the company’s stock valued at $100,000 after buying an additional 8,183 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of Replimune Group by 106.2% during the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,410 shares of the company’s stock valued at $111,000 after buying an additional 5,876 shares during the period. Institutional investors and hedge funds own 92.53% of the company’s stock.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.